Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer

Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer

Abstract Objective To investigate the risk factors for gastrointestinal perforation in metastatic colorectal cancer patients receiving bevacizumab. Methods We retrospectively reviewed 217 patients with metastatic colorectal cancer receiving bevacizumab to investigate the risk factors for gastrointes...

Full description

Bibliographic Details
Main Authors:	Kunpeng Fang, Jie Wang, Jianyong Yuan, Chengjun Sui, Jiajun Zhi, Yong Xia, Minmin Sun
Format:	Article
Language:	English
Published:	Wiley 2024-02-01
Series:	Cancer Reports
Subjects:	adverse reactions bevacizumab colorectal cancer gastrointestinal perforation
Online Access:	https://doi.org/10.1002/cnr2.1952

Similar Items

Bevacizumab induced intestinal perforation in patients with colorectal cancer
by: Sun Young Baek, et al.
Published: (2019-06-01)

Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature
by: Yusuke Fujii, et al.
Published: (2018-03-01)

Gastrointestinal perforation after bevacizumab: a multi-site, single-institution study with a focus on survival
by: Michael H. Storandt, et al.
Published: (2023-06-01)

Abdominal wall perforation in a patient with recurrent epithelial ovarian cancer after bevacizumab treatment
by: Efnan Algin, et al.
Published: (2016-08-01)

Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study
by: Zhuoling Zheng, et al.
Published: (2024-10-01)

CLINICAL EXPERIENCE OF PROLONGED BEVACIZUMAB THERAPY IN METASTATIC COLORECTAL CANCER
by: I. S. Bulavina, et al.
Published: (2015-02-01)

Retrospective analysis on the clinical efficacy of bevacizumab combined with FOLFOX4 in the first line treatment of metastatic colorectal cancer
by: Eun Mi Lee, et al.
Published: (2017-12-01)

Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis
by: Yu Song, et al.
Published: (2024-02-01)

Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer
by: Masatsune Shibutani, et al.
Published: (2024-10-01)

Sudden aortic dissection: A cautionary tale for the unexplained back pain during bevacizumab treatment
by: Wanhui Dong, MM, et al.
Published: (2023-07-01)

Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
by: Seijong Kim, et al.
Published: (2022-10-01)

INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG
by: N. V. Dobrova, et al.
Published: (2015-02-01)

Is a Total Colectomy a Better Surgical Treatment for Spontaneous Colonic Perforation that Developed during Bevacizumab Treatment for Extra-intestinal Cancers?
by: Ege Baltacı, et al.
Published: (2020-12-01)

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
by: Yingmiao Liu, et al.
Published: (2013-04-01)

Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report
by: Uysal Mukremin, et al.
Published: (2012-07-01)

Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
by: Ioana Mihaela Dinu, et al.
Published: (2023-02-01)

The Advantage of Bevacizumab in Treating Colorectal Brain Metastasis
by: Hung-Ming Chen, et al.
Published: (2014-09-01)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
by: Alessandro Ottaiano, et al.
Published: (2018-05-01)

Real-world uptake and effectiveness of triplet versus doublet chemotherapy with bevacizumab in patients with metastatic colorectal cancer in the United States
by: W.J. Chapin, MD, MSCE, et al.
Published: (2024-09-01)

Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports
by: Kyeong-Min Yeom, et al.
Published: (2024-01-01)

CLINICAL EXPERIENCE OF COMBINED AVASTIN THERAPY IN METASTATIC COLORECTAL CANCER
by: V. A. Ekimov
Published: (2015-02-01)

Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer
by: Jiang C, et al.
Published: (2018-09-01)

Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients
by: Masatsune Shibutani, et al.
Published: (2018-11-01)

TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice
by: Ji Eun Shin, et al.
Published: (2024-09-01)

Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta‐analysis
by: Akshit Chitkara, et al.
Published: (2023-12-01)

High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer
by: Kei Furuya, et al.
Published: (2024-02-01)

Cost‐effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer
by: Yulian Li, et al.
Published: (2024-01-01)

Concomitant Primary Lung Cancer and Metastatic Pulmonary Colorectal Cancer that Responded to Gemcitabine/Cisplatin/Bevacizumab Combination Therapy
by: Hung-Ming Chen, et al.
Published: (2015-03-01)

TWO PROGRAMS OF CHEMOTHERAPY IN COMBINATION WITH BEVACIZUMAB IN THE TREATMENT OF DISSEMINATED COLORECTAL CANCER
by: O. V. Zharkova, et al.
Published: (2015-02-01)

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
by: Bożena Cybulska-Stopa, et al.
Published: (2020-03-01)

Trifluridine–tipiracil plus bevacizumab versus trifluridine–tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis
by: Francisco Cezar Aquino de Moraes, et al.
Published: (2024-06-01)

Bevacizumab in metastatic colorectal cancer in a real-life setting – toxicity profile, survival outcomes, and impact of tumor sidedness
by: Hind Chibani, et al.
Published: (2022-03-01)

Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy
by: Zhiming Wang, et al.
Published: (2016-09-01)

Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias
by: Daichi Watanabe, et al.
Published: (2023-11-01)

Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion
by: Carmine Pinto, et al.
Published: (2025-01-01)

BEVACIZUMAB USE IN METASTATIC COLORECTAL CANCER IN THE FACILITIES OF DAY HOSPITAL OF REGIONAL ОNCOLOGY DISPENSARY
by: T. A. Malysheva, et al.
Published: (2015-02-01)

Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medications
by: Shinji Rho, et al.
Published: (2023-03-01)

Neonatal gastrointestinal perforation is a major challenge; A retrospective study
by: Ahmed Elrouby
Published: (2019-06-01)

Gastrointestinal Mucormycosis-Induced Massive Lower Gastrointestinal Bleeding, Rectal Perforation, and Pulmonary Embolism: A Long Diagnostic Pathway in a Case Report
by: Ralaizanaka BM, et al.
Published: (2022-08-01)

Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trialsResearch in context
by: Jingyuan Wang, et al.
Published: (2023-03-01)